Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Other hematologic neoplasm 2Other 2Lymphoid 2Dermatologic 2CNS 2Tumor-Agnostic 1Plasma cell 1Other neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Signs and Symptoms 1Postoperative Complications 1Pathologic Processes 1Pain, Postoperative 1Pain 1Neurologic Manifestations 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Methadone × Genitourinary × Clear all
NCT04475029 2023-09-13

METAMORF

University of Aarhus

Phase NA Completed
114 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neurologic Manifestations, Pain, Pain, Postoperative, Pathologic Processes, Postoperative Complications, Signs and Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡